- NPS Pharmaceuticals (NPSP -8.1%) drops today on almost a 4x surge in volume. Investors appear anxious about the potential outcome of the September 12, 2014 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee where they will be discussing the company's BLA for Natpara (recombinant human parathyroid hormone) for the long-term treatment of hypoparathyroidism.